During the past decade, there have been substantial advances in our understanding of the pathogenesis and genetics of eye diseases. Focusing on glaucoma and retinal disorders, Zhang and colleagues review the current status of ocular drug therapy, discuss novel agents currently in development and clinical trials and highlight recent advances in drug delivery.
- Kang Zhang
- Liangfang Zhang
- Robert N. Weinreb
